Marker Therapeutics Inc (MRKR)

[BluMarlin1960]

Thanks lasers for your reply, although I am referring to these last two paragraphs of that same url/press that dyp posted.

In March, AstraZeneca announced that Lynparza delayed the recurrence of ovarian cancer by more than two years compared to placebo in a Phase III study. The study demonstrated a significant improvement in progression-free survival (PFS) in germline BRCA-mutated (gBRCA), platinum-sensitive, relapsed ovarian cancer. The AstraZeneca drug is expected to line up against rival Tesaro’s niraparib, also a PARP inhibitor as a maintenance therapy for ovarian cancer patients.

Not only has Lynparza wowed with ovarian cancer, in February the company announced Lynparza in tablet form met primary endpoints in a Phase III trial to treat patients with HER2-negative metastatic breast cancer harboring germline BRCA1 or BRCA2 mutations. If approved for this type of breast cancer, Lynparza will be the first PARP inhibitor for that type of cancer.

And also thank for all your input over the years also...much appreciated.

BLU